MITA Urges CMS To Quickly Revise NCD For Amyloid Plaque PET Scans

A medical technology industry organization is urging CMS to quickly revise its national coverage determination for positron emission tomography (PET) scans for detection of beta amyloid plaque, saying the current conditions of coverage limit access to the newly approved Alzheimer’s disease drug that targets such plaque on the brain. CMS told Inside Health Policy Friday (July 7) it intends to soon propose a new national coverage determination loosening current restrictions on access to PET scans for beta amyloid plaque...